drugset
Drugs / TranspoCART19
last change Jan 2025 re-read 3 minutes ago

TranspoCART19

also known as TranspoCART19 cells

Cell therapy targets CD19

Developed for
B-cell non-Hodgkin lymphoma
Investigated by
Canary Isles Institute for Health Research Foundation · Fundación para la Investigación Biomédica del Hospital 12 de Octubre · Instituto de Investigación Biomédica de Salamanca · Spanish Clinical Research Network - SCReN

Trials 1

today NCT06378190 · Ph 1/2
20252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06378190 Mar 2024 → Jul 2029 expected B-cell non-Hodgkin lymphoma Instituto de Investigación Biomédica de Salamanca Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TranspoCART19 “Here we have generated TranspoCART19 cells, a fully functional 4-1BB second-generation CAR-T cell product targeting CD19” PMID 40034423 ↗ Jan 2025
Known as TranspoCART19 cells “Here we have generated TranspoCART19 cells, a fully functional 4-1BB second-generation CAR-T cell product targeting CD19” PMID 40034423 ↗ Jan 2025
Modality Cell therapy “a fully functional 4-1BB second-generation CAR-T cell product” PMID 40034423 ↗ Jan 2025
Target CD19 “targeting CD19” PMID 40034423 ↗ Jan 2025